Cargando…

Update on first-line treatment of advanced ovarian carcinoma

Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kemp, Z, Ledermann, JA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558307/ https://www.ncbi.nlm.nih.gov/pubmed/23378788 http://dx.doi.org/10.2147/IJWH.S30231

Ejemplares similares

First-line treatment of ovarian cancer: questions and controversies to address
por: Ledermann, Jonathan A.
Publicado: (2018)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022)

New approaches to first-line treatment of advanced renal cell carcinoma
por: George, Daniel J., et al.
Publicado: (2021)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
por: Prabhash, Kumar
Publicado: (2019)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
por: Nakai, Hidekatsu, et al.
Publicado: (2022)

Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma
por: Khan, Yasir, et al.
Publicado: (2020)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
por: Zhang, Lan, et al.
Publicado: (2022)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Premature Ovarian Insufficiency - an update on recent advances in understanding and management
por: Torrealday, Saioa, et al.
Publicado: (2017)

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation
por: von Felden, Johann, et al.
Publicado: (2016)

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
por: Jang, Ji Yon Agnes, et al.
Publicado: (2017)

Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
por: Singh, Abhay, et al.
Publicado: (2020)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
por: Conic, Irena, et al.
Publicado: (2022)

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
por: Hirte, Hal W
Publicado: (2013)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy
por: Milani, Andrea, et al.
Publicado: (2017)

Ovarian cancer – American cancer society atlas of clinical oncology
por: Ledermann, J A
Publicado: (2004)

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
por: Kurnit, Katherine C., et al.
Publicado: (2021)

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
por: Feugier, Pierre, et al.
Publicado: (2019)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

Small-cell lung carcinoma with ovarian metastasis 4 years after the first-line treatment
por: Kitazawa, Jun, et al.
Publicado: (2019)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
por: Leonard, P, et al.
Publicado: (2002)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2023)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy
por: Huang, Chih-Chieh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hs11odlkjcdsgb9p67llihnhhn